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ABSTRACT The World Health Organization reports that antibiotic-resistant patho-
gens represent an imminent global health disaster for the 21st century. Gram-
positive superbugs threaten to breach last-line antibiotic treatment, and the phar-
maceutical industry antibiotic development pipeline is waning. Here we report the
synergy between ionophore-induced physiological stress in Gram-positive bacteria
and antibiotic treatment. PBT2 is a safe-for-human-use zinc ionophore that has pro-
gressed to phase 2 clinical trials for Alzheimer’s and Huntington’s disease treatment.
In combination with zinc, PBT2 exhibits antibacterial activity and disrupts cellular ho-
meostasis in erythromycin-resistant group A Streptococcus (GAS), methicillin-resistant
Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE). We were
unable to select for mutants resistant to PBT2-zinc treatment. While ineffective alone
against resistant bacteria, several clinically relevant antibiotics act synergistically with
PBT2-zinc to enhance killing of these Gram-positive pathogens. These data represent a
new paradigm whereby disruption of bacterial metal homeostasis reverses antibiotic-
resistant phenotypes in a number of priority human bacterial pathogens.
IMPORTANCE The rise of bacterial antibiotic resistance coupled with a reduction in
new antibiotic development has placed signiﬁcant burdens on global health care.
Resistant bacterial pathogens such as methicillin-resistant Staphylococcus aureus and
vancomycin-resistant Enterococcus are leading causes of community- and hospital-
acquired infection and present a signiﬁcant clinical challenge. These pathogens have
acquired resistance to broad classes of antimicrobials. Furthermore, Streptococcus
pyogenes, a signiﬁcant disease agent among Indigenous Australians, has now ac-
quired resistance to several antibiotic classes. With a rise in antibiotic resistance and
reduction in new antibiotic discovery, it is imperative to investigate alternative ther-
apeutic regimens that complement the use of current antibiotic treatment strategies.
As stated by the WHO Director-General, “On current trends, common diseases may
become untreatable. Doctors facing patients will have to say, Sorry, there is nothing
I can do for you.”
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Combating antibiotic resistance remains a critical global health priority (1). Over thepast decade, the overall trend of bacterial pathogens exhibiting drug resistance has
steadily increased (1–3). In high-income settings such as the United States, reports
estimate that more than 2 million antibiotic-resistant infections occur per annum with
a death toll of 23,000 at a direct cost of $20 billion (3). In low-income settings,
communicable diseases remain the leading cause of death, now heightened by emerg-
ing and reemerging infectious diseases (4). Largely driven by the excessive and
inappropriate use of antibiotics, the threat of antibiotic resistance has recently been
ampliﬁed by a substantial decline in new antimicrobial discovery. From 2011 to 2016,
only 8 new antibiotics were approved by the U.S. FDA (5). This signiﬁcant decline in
novel antibiotic discovery and commercialization has paralleled an escalation in anti-
biotic resistance, highlighting the urgent need for new antibiotic development and
complementary therapy. Today, several strategies are being investigated to combat
bacterial resistance to existing antibiotics (5–7), including the repurposing of existing
drugs, originally developed as therapeutics for noninfectious disease.
The hydroxyquinoline PBT2 has been developed as a potential treatment for Alz-
heimer’s and Huntington’s disease and has progressed to phase 2 human clinical trials,
with a daily dose of 250 mg over 6 months being safe and well tolerated (8–10). PBT2
is an ionophore that facilitates the transport of ﬁrst-row transition metal ions, such as
zinc, across biological membranes, thereby altering intracellular metal homeostasis.
Bacterial pathogens encounter signiﬁcant ﬂuctuations in metal ion abundance during
host colonization and have been shown to be highly susceptible to phagocytic cell
induction of zinc toxicity (11). Although metals such as zinc are critical nutrients for
bacterial cell survival, metal-transporting ionophores can facilitate accumulation of
high levels of zinc in the bacterial cytosol, leading to bacterial cell toxicity (11, 12). Here,
we report that in combination with zinc, the ionophore PBT2 destabilizes key cellular
homeostasis pathways involved in bacterial antibiotic resistance mechanisms. Further-
more, the combination of PBT2 and zinc is able to resensitize erythromycin-resistant
group A Streptococcus (GAS), methicillin-resistant Staphylococcus aureus (MRSA), and
vancomycin-resistant Enterococcus (VRE) to previously resistant classes of antibiotic in
vivo. These data highlight a new and encouraging alternative therapeutic regimen
which complements the use of current antibiotic strategies.
RESULTS AND DISCUSSION
PBT2 was originally developed as a potential therapeutic for Alzheimer’s and
Huntington’s disease. Here, we sought to examine the therapeutic potential of PBT2 as
an antibacterial agent, which has not been previously tested. Following chemical synthesis
of PBT2 (13) (see Materials and Methods and Fig. S1 in the supplemental material), the
purity of the ﬁnal product was determined to be 95% by 1H and 13C NMR.
Erythromycin-resistant GAS, MRSA, and VRE are categorized by the U.S. Centers for
Disease Control and Prevention as concerning or serious threats to human health (3).
Using Clinical and Laboratory Standards Institute guidelines for antimicrobial sensitivity
testing (14), we investigated the potential of PBT2 to act as an antibacterial agent
against GAS strain HKU16 (15), MRSA strain USA300 (16), and VRE clinical isolate RBWH1
(Fig. S2). At the concentrations used, neither PBT2 nor zinc displayed signiﬁcant
antibacterial activity. However, the combination of PBT2 and zinc (PBT2-zinc) exhibited
antibacterial activity against each pathogen (Fig. 1a and Table S1). Bactericidal activity
is deﬁned as a 3-log reduction in bacterial CFU relative to the initial inoculum.
Measured to the effects of vancomycin (bactericidal) and tetracycline (bacteriostatic) on
MRSA, the mode of action of PBT2-zinc was found to be bactericidal (Fig. 1b). We next
investigated the capacity of each pathogen to develop resistance to the combination
of PBT2-zinc. We were unable to isolate resistant mutants for any of the strains
following serial passage for a period of 30 days in the presence of subinhibitory
concentrations of PBT2-zinc (Fig. 1c). To explore the safety of PBT2-zinc in human cells,
we investigated the survival of human primary tonsil epithelial cells in the presence of
this combination. After 24 h, cell viability was unaffected by PBT2-zinc treatment
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FIG 1 Synergistic antimicrobial activity of PBT2 and zinc. (a) Growth of GAS, MRSA, and VRE serially diluted on THY agar
in the presence or absence of PBT2 (1.5 M) and/or zinc (400 M) or vancomycin (20 g/ml). Dilution values are indicated
on the left of each ﬁgure panel. (b) Time-kill curves of GAS, MRSA, and VRE in THY broth with or without PBT2 (2 M for
GAS or 6 M for MRSA and VRE) and/or ZnSO4 (400 M for GAS and 600 M for MRSA and VRE) or vancomycin
(Continued on next page)
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(Fig. S3). We next investigated the efﬁcacy of PBT2-zinc treatment using a murine
wound infection model (17). The application of PBT2-zinc (zinc in the form of either
ZnCl2 or ZnSO4) resulted in a signiﬁcant reduction in the bacterial burden at the site of
infection upon topical treatment (Fig. 1d).
Next, we determined the intracellular zinc content of each pathogen in response to
subinhibitory concentrations of PBT2-zinc. As assessed by inductively coupled plasma
mass spectrometry (ICP-MS), increased cellular levels of zinc were observed in GAS,
MRSA, and VRE upon treatment (Fig. 2a). PBT2 and zinc combinations were also shown
to affect intracellular iron, manganese, and copper content, suggesting a mechanism
involving disruption of heavy metal homeostasis (Fig. S4A to C). To further explore the
mechanism of action of PBT2-zinc treatment, we analyzed the transcriptome of each
pathogen in response to subinhibitory concentrations of PBT2-zinc. Signiﬁcant changes
in the transcription of heavy metal homeostasis genes were observed and conﬁrmed by
quantitative real-time PCR (Fig. 2b and c; Table S2). Consistent with metal ion intoxi-
cation, the transcriptional responses to PBT2-zinc treatment in the Gram-positive
pathogens included the induction of zinc efﬂux systems (GAS, czcD; MRSA, czcD and
zntA), copper efﬂux systems (GAS, copA; MRSA, copZ; VRE, copA), and manganese
transport systems (VRE, mntA). In addition, the transcription of several essential viru-
lence, oxidative stress, and metabolic systems was also perturbed by subinhibitory
concentrations of PBT2-zinc (Fig. 2b and c; Table S2). Despite these changes in the
transcriptional proﬁle, PBT2-zinc did not alter cell membrane permeability of GAS,
MRSA, and VRE compared to the pore-forming antibiotic nisin (Fig. S5A). PBT2-zinc did
not visibly disrupt the bacterial cell wall of GAS and MRSA (Fig. S5B and C); however,
visible depressions in the VRE cell wall were observed after 3 h of treatment and VRE
cells became enlarged after 24 h (Fig. S5D).
Building on the observed signiﬁcant transcriptional and physiological impacts in-
duced by the combination of PBT2-zinc upon these bacterial strains (Table 1), we then
assessed whether these disruptions enhanced antibiotic sensitivity in otherwise resis-
tant bacterial pathogens. To achieve this, the tetracycline- and macrolide-resistant GAS
strain HKU16 and the multidrug-resistant strains MRSA USA300 and VRE RBWH1 were
further investigated. In the presence of antibacterial only, HKU16, USA300, and RBWH1
were resistant to several antibiotic classes (Table 1). Addition of either PBT2 or zinc
alone did not affect their susceptibility proﬁle. However, in the presence of subinhibi-
tory concentrations of PBT2-zinc, GAS strain HKU16 became susceptible to tetracycline,
azithromycin, and clindamycin; MRSA strain USA300 became susceptible to oxacillin,
erythromycin, and ampicillin; and VRE strain RBWH1 became susceptible to vancomy-
cin, tetracycline, azithromycin, and clindamycin (Table 1). While resistance to erythro-
mycin was overcome in MRSA USA300, erythromycin resistance was maintained in GAS
HKU16 and VRE RBWH1. This difference may relate to the inducible erythromycin
resistance mechanism in MRSA USA300 (clindamycin sensitive) compared to the alter-
native constitutive erythromycin resistance mechanism (clindamycin resistant) (15,
18–20) operating in GAS HKU16 and VRE RBWH1 (Table 1). Bactericidal activity of
PBT2-zinc and antibiotic combinations was partially rescued with the addition of the
antioxidant glutathione (Fig. S6), suggesting the involvement of reactive active oxygen
species in the mechanism of cell killing (21).
To investigate the efﬁcacy of PBT2-zinc in combination with antibiotics on infection,
we again employed the murine wound infection model. Neither antibiotic nor subin-
FIG 1 Legend (Continued)
(bactericidal; 4 g/ml for MRSA) or tetracycline (bacteriostatic; 1 g/ml for MRSA). Error bars indicate standard deviations
from 2 biological replicates. (c) Development of resistance during serial passage in the presence of subinhibitory
concentrations of antimicrobial compounds in CAMHB. Data represent means for 3 biological replicates. (d) CFU recovered
from a murine wound infection model 4 days after challenge with GAS (1.1 107 CFU), MRSA (6 105 CFU), or VRE
(8.8 105 CFU). Mice were treated twice daily with carrier ointment only or ointment with 5 mM PBT2 and/or 50 mM Zn
(ZnSO4 for MRSA or ZnCl2 for GAS) or 2.75 mM PBT2 and/or 75 mM ZnSO4 for VRE. Values for individual mice are plotted,
and black lines are representative of group geometric mean (*, P 0.05; **, P 0.005; ***, P 0.001; ****, P 0.0001,
one-way ANOVA).
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FIG 2 PBT2 and zinc affect heavy metal homeostasis, metabolism and virulence. (a) Intracellular zinc concentrations as determined by
ICP-MS for GAS, MRSA, and VRE grown in THY with or without PBT2 and zinc (GAS, 0.3 M PBT2 50 M ZnSO4; MRSA, 1 M PBT2 200
M ZnSO4; and VRE, 1 M PBT2  150 M ZnSO4) (error bars indicate standard error of the mean from at least 3 biological replicates; *,
P  0.05; **, P  0.005; ***, P  0.001; ****, P  0.0001, one-way ANOVA). (b) RNASeq transcriptome analysis of bacteria treated with PBT2
and ZnSO4 for GAS (4.75 M PBT2  128 M ZnSO4), MRSA (2 M PBT2  50 M ZnSO4), and VRE (1.75 M PBT2  128 M ZnSO4) in
CAMHB. Genes with log2 fold changes of1/1 and P 0.05 are shown in blue, and selected genes of interest are shown in red. Data were
collected from 3 biological replicates. (c) Transcript levels for selected genes measured by real-time PCR. Log2 fold changes were calculated
relative to untreated controls and normalized to a reference gene using the ΔΔCTmethod (reference genes were proS for GAS, rrsA for MRSA,
and 23S for VRE). Error bars represent standard deviations from 3 biological replicates.
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hibitory concentrations of PBT2-zinc alone signiﬁcantly reduced bacterial burden at the
site of infection (Fig. 3). However, the combination of PBT2-zinc and tetracycline
signiﬁcantly reduced GAS infection; PBT2-zinc and erythromycin signiﬁcantly reduced
MRSA infection; and PBT2-zinc and vancomycin signiﬁcantly reduced VRE infection
(Fig. 3). Amounts of zinc and PBT2 utilized in each respective treatment were well below
concentrations typically employed for the treatment of actinic keratosis (ZnSO4, 25%
[wt/vol]) (22) and are signiﬁcantly below the regimens tested in phase I and II clinical
trials of PBT2 (8–10). Thus, concentrations of both PBT2 and zinc used in this study are
likely to be well tolerated via topical delivery over a prolonged period of time. Overall,
these data demonstrate the novel therapeutic synergy of PBT2-zinc in combination
with antibiotics to topically treat otherwise resistant infections.
The steady and unrelenting rise in antibiotic resistance is one of the greatest global
challenges confronting medicine and global heath. Strategies that are being explored
to address the problem of bacterial resistance to existing antibiotics include the
development of new antibiotics, blocking of resistance mechanisms against existing
antibiotics, bacteriophage therapy, targeting of virulence mechanisms that weaken
bacterial defense against host immunity, stimulating host immunity to improve bac-
terial clearance, destabilization of the Gram-negative cell envelope, vaccine develop-
ment, and repurposing existing drugs used for noninfectious disease indications (6,
23–28). The Gram-positive bacterial pathogens GAS, MRSA, and VRE cause a wide range
of hospital-acquired and community-acquired infections, place signiﬁcant pressure and
economic burden on health care systems, and are a major contributor to global human
morbidity and mortality (29). Here we reveal that the safe-for-human-use ionophore
PBT2, in combination with zinc, possesses antibacterial activity and at subinhibitory
concentrations reverses Gram-positive bacterial resistance against a number of impor-
tant antibiotics. The mechanism of action underlying this effect appears to be associ-
ated with dysregulation of transition metal ion homeostasis and profound disruption of
essential virulence and metabolic systems, all of which may weaken the capacity of
these bacterial pathogens to cause infection. Effects on antibiotic resistance were not
universal. For instance, erythromycin resistance was reversed in MRSA but not in GAS.
PBT2 is a safe-for-human-use ionophore that has progressed to phase 2 human clinical
FIG 3 PBT2 and zinc reverse antibiotic resistance in a murine wound infection model. CFU recovered 4 days after wound infection
with GAS (3.8 106 CFU), MRSA (5.3 105 CFU), or VRE (9.4 105 CFU). Mice were treated twice daily with ointment only or ointment
containing PBT2, Zn, and/or antibiotic (2 mM PBT2, 25 mM ZnSO4, and/or 15 g/ml tetracycline for GAS; 3 mM PBT2, 30 mM ZnSO4,
and/or 4 g/ml erythromycin for MRSA; and 2 mM PBT2, 30 mM ZnSO4, and/or 20 g/ml vancomycin for VRE). Values for individual
mice are plotted, and black lines are representative of group geometric mean (*, P 0.05; ***, P 0.001; ****, P 0.0001, one-way
ANOVA). Abbreviations: Tet, tetracycline; Erm, erythromycin; Van, vancomycin.
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trials (9, 10). Zinc is used as a nutritional supplement and homeopathic remedy, and
here we show that the delivery of zinc using the ionophore PBT2 can reduce the
concentration of zinc required for efﬁcacy to levels that are tolerated physiologically
(30). Taken together, these data demonstrate a new paradigm whereby destabilizing
bacterial physiology may circumvent the antibiotic resistance problem, by rescuing the
function of antibiotics to which bacteria have become resistant.
MATERIALS AND METHODS
PBT2 synthesis. PBT2 (compound 3) was synthesized following the reaction conditions shown below
(13). Initially, oxidation of the methyl side chain of 5,7-dichloro-2-methylquinolin-8-ol (compound 1) was
achieved by heating compound 1 with selenium dioxide in 1,4-dioxane to provide the required aldehyde
(compound 2), in quantitative yield. The resultant crude product was then further reacted with
dimethylamine-hydrochloride in 1,2-dichloroethane and triethylamine to yield a product that was reduced in
situ, by treatment with sodium triacetoxyborohydride to provide the free amine of PBT2 as an oil. Upon
acidiﬁcation of the free amine with HCl, PBT2 hydrochloride-salt (compound 3) was obtained in 81% yield.
(i) General synthetic methods. Reagents and dry solvents purchased from commercial sources were
used without further puriﬁcation. Anhydrous reactions were carried out under an atmosphere of argon,
using oven-dried glassware. Reactions were monitored using thin-layer chromatography (TLC) on
aluminum plates precoated with Silica Gel 60 F254 (E. Merck). Developed plates were observed under UV
light at 254 nm and then visualized after application of a solution of H2SO4 in EtOH (5% [vol/vol]) and
heating. Flash chromatography was performed on Silica Gel 60 (0.040 to 0.063 mm) using distilled
solvents. 1H and 13C NMR spectra were recorded at 400 and 100 MHz, respectively, on a Bruker Avance
400-MHz spectrometer. Chemical shifts () are reported in parts per million, relative to the residual
solvent peak as internal reference (CDCl3, 7.26 [s] for 1H, 77.0 [t] for 13C). Low-resolution mass spectra
(LRMS) were recorded, in electrospray ionization mode, on a Bruker Daltonics Esquire 3000 ESI spec-
trometer, using positive ionization mode. The purity of the ﬁnal product (compound 3) was determined
to be 95% by 1H and 13C NMR. The synthetic work followed the procedures reported in the patent
describing PBT2 preparation (13). The details of synthetic methods used and full characterization data of
the ﬁnal product are reported below.
(ii) 5,7-Dichloro-8-hydroxy-2-quinolinecarboxaldehyde (compound 2).
To a stirred suspension of selenium dioxide (1.75 g, 15.80mmol) in 1,4-dioxane (80ml) at 55°C was added a
solution of 5,7-dichloro-2-methyl-quinolin-8-ol (2.0 g, 8.77mmol) in 1,4-dioxane (20ml) in a dropwise manner
over a period of 3 h. After complete addition, the heating temperature was raised to 80°C, and heating was
maintained overnight. The reaction mixture was then allowed to cool down to room temperature, and the
insoluble solids were ﬁltered off on a Celite bed. The ﬁltrate was concentrated under vacuum, and the residue
was washed with diethyl ether (10ml  3) to yield 2.10 g (quantitative yield) of the aldehyde 2 as a yellow
powder, which was used in the following step without further puriﬁcation.
(iii) 5,7-Dichloro-2-((N,N-dimethylamino)methyl)quinolin-8-ol HCl salt (compound 3, PBT2 HCl).
To a stirred solution of the crude aldehyde 2 (2.0 g, 8.26 mmol) and dimethylamine hydrochloride
(730 mg, 8.96 mmol) in 1,2-dichloroethane (100 ml) was added triethylamine (1.25 ml, 8.96 mmol) in a
dropwise manner. The mixture was stirred at room temperature (RT) for 5 min, and then sodium
triacetoxyborohydride (2.4 g, 11.32 mmol) was added portionwise over a period of 5 min. The mixture
was then stirred at RT overnight. Upon reaction completion, the reaction mixture was diluted with
dichloromethane (200 ml) and washed with saturated sodium bicarbonate (100 ml  3). The organic
layer was then dried over anhydrous Na2SO4 and concentrated under vacuum to yield an oily product
of the free amine base of PBT2. The oily product was triturated with water (100 ml) and extracted with
diethyl ether (100 ml  4). The ethereal extracts were combined, washed with brine, dried over Na2SO4,
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and concentrated under vacuum. To the obtained residue was added 10 ml of concentrated HCl, and the
mixture was concentrated in vacuo. The resulting residue was washed with dichloromethane (50 ml  3)
to yield 2.30 g of PBT-HCl salt (compound 3) as pale yellow powder (81% yield). 1H NMR (400 MHz, CDCl3):
 2.32 (s, 6H, 2NCH3), 3.78 (s, 2H, CH2), 7.51 (s, 1H, H-6), 7.61 (d, J 8.7 Hz, 1H, H-4), 8.39 (d, J 8.6 Hz,
1H, H-3); 13C NMR (101 MHz, CDCl3):  45.64 (NCH3  2), 65.46 (CH2), 115.51 (C-7), 120.35 (C-5), 122.26
(C-3), 124.07 (q carbon), 127.76 (C-6), 133.83 (C-4), 138.16 (q carbon), 147.98 (C-8), 158.93 (C-2); LRMS
[C12H12Cl2N2O] (m/z): (positive ion mode) 272.0 [MH].
Bacterial strains, media, and growth conditions. GAS HKU16, MRSA USA300, and VRE RBWH1 were
grown in Todd-Hewitt broth (THB) or agar with 1% yeast extract (THY) (31) or in cation-adjusted
Mueller-Hinton broth (CAMHB) (32) or agar (supplemented with 2.5% lysed horse blood [LHB] for GAS
HKU16). Bacteria were routinely grown at 37°C under static conditions in ambient air.
Sequencing of VRE. To determine the complete genome sequence of RBWH1, long-read, single-
molecule real-time (SMRT) sequencing was performed using the Paciﬁc Biosciences RS II platform.
Genomic DNA was manually sheared through a 26-gauge syringe, and a library was prepared using the
SMRTbell DNA Template Prep kit 1.0 (Paciﬁc Biosciences). Sequencing was performed on a single SMRT
cell using polymerase P6 and V4 chemistry (Paciﬁc Biosciences). Filtering of the long reads identiﬁed
147,593 reads with an average polymerase read length of 4.8 kb. To aid in genome assembly validation,
RBWH1 was also sequenced on an Illumina Next-Seq 500 to produce paired-end reads with a read length
of 150 bases. De novo genome assembly was performed using SMRT analysis v2.3.0 (Paciﬁc Biosciences)
and HGAP v3 and polished using Quiver. The chromosome and plasmids were circularized either
manually or using Circlator (33), and the resulting genome assembly was validated using the Illumina
short-read sequence data using Pilon v1.22 (34). Putative plasmid sequences were trimmed and
orientated to published E. faecium plasmids. The ﬁnal genome comprised a single circular chromosome
of 2,876,110 bp and six plasmid sequences larger than 2,000 bp in length: pRBWH1.1, 167,502 bp;
pRBWH1.2, 55,808 bp; pRBWH1.3, 39,621 bp; pRBWH1.4, 11,916 bp; pRBWH1.5, 4,453 bp; pRBWH1.6,
3,008 bp. Genome annotation was performed using Prokka (35).
Drop test assay. Bacteria were diluted from overnight cultures to obtain a starting OD600 of 0.01 in
THY. Once the bacteria grew to an OD600 of 0.6, the cultures were serially diluted in PBS and 5 l of each
dilution (undiluted, 101, 102, 103, 104, 105) was plated on THY agar plates with or without zinc
(400 M) and/or PBT2 (1.5 M) or vancomycin (20 g/ml). Plates were incubated at 37°C overnight. Drop
tests were undertaken in biological triplicates.
Inductively coupled plasma mass spectrometry (ICP-MS). Overnight cultures of bacteria were
diluted to an OD600 of 0.05 in THY (GAS, 45 ml; MRSA and VRE, 20 ml) with or without PBT2 and zinc (GAS,
0.3 M PBT2 50 M ZnSO4; MRSA, 1 M PBT2 200 M ZnSO4; and VRE, 1 M PBT2 150 M ZnSO4)
and grown to mid-log phase (GAS, OD600  0.5; MRSA and VRE, OD600  1.0). Cells were harvested at
7,000 g for 7 min at 8°C. The pellet was resuspended in 20 ml PBS containing 5 mM EDTA and pelleted
again at 7,000 g for 7 min at 8°C. The wash was repeated two more times, and then the pellet was
resuspended in 20 ml PBS without EDTA. The cells were harvested again at 7,000 g for 7 min at 8°C, and
then the pellet was washed with PBS. After centrifugation, the pellet was resuspended in 1 ml PBS and
transferred into a microcentrifuge tube. The cells were pelleted at 18,000 g for 7 min at 8°C, the
supernatant was removed, and the pellet was dried at 96°C overnight. The dry pellet was weighed to
determine the dry cell weight, resuspended in 1 ml of 35% HNO3, and carefully heated to 96°C for 60 min.
After vortexing, the sample was centrifuged at 18,000 g for 25 min to pellet cell debris. For ICP-MS
analysis, 200 l of the supernatant was diluted into 1.8 ml of double-distilled H2O. Samples were
analyzed on an Agilent 8900 ICP-QQQ (Adelaide Microscopy, University of Adelaide). At least three
biological replicates were analyzed.
MIC determination. MICs were determined by broth microdilution in accordance with CLSI guidelines
(14). MIC assays were undertaken in 96-well plates in a total volume of 100l per well. For MRSA and VRE,
the assays were performed in MHB, and for GAS, MHB plus 2.5% lysed horse blood (LHB) was used. The
bacterial inoculum was prepared by direct colony suspension aiming for 2 105 to 8 105 CFU/ml bacteria
per well. Antibiotics/compounds were serially diluted 2-fold across the 96-well plate; the last column
contained no antibiotics/compounds. The inoculum was added to the plate containing antibiotic/compound
and incubated for 16 to 24 h at 35 2°C. The MIC was determined as the lowest concentration of
antibiotic/compound that showed no visible growth. MIC assays were carried out in biological triplicates.
Resistance development studies. The development of resistance to antibiotics/compounds was
undertaken essentially as previously described (6). To investigate resistance development for GAS, MRSA,
and VRE in the presence of subinhibitory concentrations of PBT2 and zinc, bacteria were sequentially
passaged over 30 days in CAMHB. As a control, the antibiotic ciproﬂoxacin was used for GAS and MRSA,
and chloramphenicol was used for VRE. Initially, the MIC for PBT2-zinc or antibiotic was determined by
broth microdilution according to CLSI guidelines in a microtiter plate. The highest antibiotic or PBT2-zinc
concentration that still showed growth after overnight incubation was diluted 1/250 into a new
microtiter plate containing 2-fold dilutions of antibiotic or PBT2-zinc. This procedure was repeated for
30 days. The assays were undertaken in biological triplicates.
Bacterial time-kill assays. Bacteria were grown to mid-log phase in THY and then diluted to a
starting OD600 of 0.05 in THY only, THY containing PBT2 (2 M for GAS or 6 M for MRSA and VRE) and/or
ZnSO4 (400 M for GAS and 600 M for MRSA and VRE), or THY containing vancomycin (4 g/ml for
MRSA; 2 MIC) or tetracycline (1 g/ml for MRSA; 2 MIC). To determine surviving numbers of bacteria,
aliquots were removed at 0, 1, 2, 4, 6, and 24 h; serially diluted in PBS; and plated onto THY agar plates.
Viable bacteria were counted after overnight incubation at 37°C. Time-kill assays were performed in
biological duplicates.
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Cytotoxicity assay. TEpi cells were incubated with increasing concentrations of PBT2-zinc (3 M
PBT2 300 M ZnSO4 or 6 M PBT2 600 M ZnSO4) at 37°C, 5% CO2, for 24 h. Cell death was
quantiﬁed at 4 h and 24 h posttreatment by measuring lactate dehydrogenase (LDH) release from cell
supernatants as previously described (36). A two-way ANOVA with Sidak’s posttest was performed to
detect statistical signiﬁcance.
Ethics. Animal experiments were performed according to the Australian code of practice for the care
and use of animals for scientiﬁc purposes. Permission was obtained from the University of Queensland
ethics committee (SCMB/140/16/NHMRC).
Murine wound infection model. For wound infection (17), 4- to 7-week-old female BALB/c mice
were used and housed in individual cages. The neck area of the mice was shaved, and residual hair was
removed using Nair (Church & Dwight) prior to the experiment. On the day of infection, mice were
anesthetized by inhalation of methoxyﬂurane, and a small superﬁcial scariﬁcation was made on the
shaved skin using a metal ﬁle. For infection, bacteria were cultured to mid-log phase in THY medium and
5 106 to 2 107 CFU GAS or 5 105 to 2 106 CFU MRSA/VRE was applied onto the scariﬁed skin
(exact inoculum is speciﬁed in ﬁgure legends). After the inoculum had been absorbed by the skin
(approximately 10 min), the mice were treated with carrier ointment only (Pharmacy Choice aqueous
cream) or ointment containing PBT2 and/or zinc and/or antibiotic (tetracycline for GAS, erythromycin for
MRSA, vancomycin for VRE). Mice were treated with ointment twice daily, and a total of 9 treatments
were applied. Each treatment consisted of around 25 to 30 mg ointment and contained 5 mM PBT2
and/or 50 mM Zn (as ZnSO4 for MRSA and ZnCl2 for GAS) and 2.75 mM PBT2 and/or 75 mM ZnSO4 for
VRE. For experiments including antibiotics, the ointment contained 2 mM PBT2 and/or 25 mM ZnSO4
and/or 1.5% tetracycline for GAS, 3 mM PBT2 and/or 30 mM ZnSO4 and/or 0.4% erythromycin for MRSA,
and 2 mM PBT2 and/or 30 mM ZnSO4 and/or 2% vancomycin for VRE. After 4 days of treatment, the mice
were euthanized, and the scariﬁed skin was excised and washed twice in PBS by vortexing for 30 s. The
skin was then homogenized in lysing matrix F tubes using a FastPrep instrument (MP Biomedicals) and
plated out on antibiotic selective THY plates to determine viable bacteria (for GAS, homogenates were
plated out on THY with 10 g/ml neomycin; for MRSA and VRE, on THY with 10 g/ml ampicillin). Each
treatment group contained ﬁve to eight mice, and statistical signiﬁcance was calculated with one-way
ANOVA using log-transformed values.
RNA isolation. RNA was isolated using the FastRNA Pro Blue kit (MP Biomedicals) and the SV total
RNA isolation system (Promega). Brieﬂy, bacteria were grown to mid-log phase (OD600 of 0.4 to 0.5) in
MHB (2.5% LHB for GAS) in the presence or absence of PBT2 and/or ZnSO4. Two volumes of RNAprotect
(Qiagen) was added to the cultures, and the samples were then centrifuged at 5,000 g for 25 min at
4°C to pellet cells. The dry pellet was stored at 80°C overnight and then resuspended in 1 ml RNA Pro
solution (FastRNA Pro Blue kit). The sample was transferred to lysing matrix B and processed in a FastPrep
instrument (MP Biomedicals). After centrifugation at 13,000 g for 15 min at 4°C, the supernatant was
transferred into a fresh tube and incubated at room temperature for 5 min. Three hundred microliters of
chloroform was added, and the mixture was vortexed for 10 s. After 5 min incubation at room temper-
ature, the upper phase was moved to a fresh tube containing 200 l cold 95% EtOH. The sample was
placed on ice for at least 5 min and then transferred into an SV total RNA isolation system spin column.
The sample was processed according to the manufacturer’s instructions and eluted in 110 l of
nuclease-free water. To ensure complete removal of DNA, the RNA was then further puriﬁed using the
TURBO DNA-free kit (Thermo Fisher Scientiﬁc) according to the manufacturer’s instructions.
RNASeq analysis. RNASeq analysis was performed at the Australian Genome Research Facility. The
library was prepared using a Ribo Zero stranded protocol. In brief, rRNA was depleted with Ribo Zero,
RNA was fragmented (heat and divalent cations), and ﬁrst-strand cDNA synthesis was done with
SuperScript II reverse transcriptase (Invitrogen). For the second-strand cDNA synthesis, the strand was
“marked” with dUTP. A 3= adenylation of DNA fragments was performed followed by sequencing adapter
ligation (utilizing T-A pairing of adapter and DNA fragments). The library was ampliﬁed by PCR
(ampliﬁcation of “unmarked” ﬁrst strand only). Libraries were assessed using either Agilent’s Bioanalyzer
DNA 1000 chip or the TapeStation D1K TapeScreen system. qPCR was used to quantify individual libraries
before normalizing (2 nM) and pooling. Libraries were pooled and clustered through the Illumina cBot
system using TruSeq PE Cluster kit v3 reagents followed by sequencing on the Illumina HiSeq 2500
system with TruSeq SBS kit v3 reagents with 110 (101 read 1, 9 cycles index read). Libraries were
sequenced with a HiSeq 2500 ultrahigh-throughput sequencing system (Illumina) to produce 100-base-
paired-end reads. An average of 45 million reads per sample were generated and mapped to the
reference genome (Sscrofa10.2) using the 2-pass method of the STAR aligner with default parameters.
Eighty percent of these reads uniquely hit to the reference genome. Duplicate reads were denoted with
the MarkDuplicates tool of Picard (http://broadinstitute.github.io/picard). Differential gene expression
was analyzed using Degust (http://victorian-bioinformatics-consortium.github.io/degust/), and ﬁgures
were generated using RStudio (37).
Real-time PCR. Only selected genes associated with heavy metal homeostasis, virulence systems,
and metabolic processes were selected for real-time PCR analysis. Brieﬂy, 1 g of isolated RNA was
transformed into cDNA using the SuperScript III ﬁrst-strand synthesis kit (Invitrogen). Real-time PCR was
undertaken with the SYBR Green master mix (Applied Biosystems) following the manufacturer’s instruc-
tions. Measurements were performed using the ViiA7 real-time PCR system (Life Technologies), using the
following conditions: 95°C for 10 min, 40 cycles of 95°C for 15 s, and 60°C for 1 min, and a ﬁnal
dissociation cycle of 95°C for 2 min, 60°C for 15 s, and 95°C for 15 s. Relative gene expression was
calculated by the ΔΔCT method using proS (GAS), rrsA (MRSA), and 23S (VRE) as the reference genes. All
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experiments were done in biological triplicates and measured in technical triplicates. Primers used for
real-time PCR are given in Table S3.
Glutathione supplementation assay. Bacteria were grown to mid-log phase in THY and then
diluted to a starting OD600 of 0.05 in THY only or THY containing PBT2 (2 M for GAS or 6 M for MRSA
and VRE), ZnSO4 (400 M for GAS and 600 M for MRSA and VRE), antibiotic at 4 g/ml (tetracycline for
GAS, erythromycin for MRSA, and vancomycin for VRE), and reduced glutathione (1 mM, 5 mM, and
10 mM). To determine surviving numbers of bacteria, aliquots were removed at 0, 1, 2, 4, 6, and 24 h;
serially diluted in PBS; and plated on THY agar plates. Viable bacteria were counted after overnight
incubation at 37°C. Glutathione supplementation assays were performed in biological duplicates.
Cell membrane permeability assays. Membrane permeability of bacterial strains was measured
using the Live/Dead BacLight bacterial viability kit (L7007) (ThermoFisher Scientiﬁc) according to the
manufacturer’s instructions. Strains were grown as previously described (in CAMHB [2.5% LHB for GAS])
with the exception of MRSA USA300, which was grown in tryptic soy broth (TSB). Mid-exponential-phase
cells were harvested (4,000 g, 10 min, 4°C), washed, and resuspended to an OD600 of 0.6 in potassium
phosphate buffer (100 mM, pH 7.5), containing MgCl2 (2 mM) with the addition of 10 mM NaCl for MRSA
USA300. A 0.4 ml volume of the cell suspension was removed and maintained on ice as the t 0 sample.
The cell suspension was energized by a 10-min incubation with glucose (20 mM). Aliquots (5 ml) were
either untreated or treated with relevant concentrations of PBT2 and zinc (alone or in combination),
nigericin (10 M), or nisin (25 g/ml) for 1 h under the same conditions in which they were grown.
Aliquots (100 l) of the t 0 and 60-min samples were resuspended with 2 Live/Dead BacLight
staining reagent (100 l) in a 96-well, ﬂat-bottom microtiter plate. Following incubation in the dark
(15 min, RT), the ﬂuorescence emission was measured using a Varioskan Flash plate reader (ThermoFisher
Scientiﬁc). Membrane permeability was measured as a relative ﬂuorescence emission ratio (530/630 nm)
of the ﬂuorescent dyes SYTO9 (which stains cells with intact or damaged membranes) and propidium
iodide (which stains only cells with damaged membranes) and expressed as the relative change in
membrane integrity after 1-h treatment with compounds. All experiments were done in biological
triplicates and measured in technical triplicates.
Scanning electron microscopy (SEM). SEM studies were undertaken at the Centre for Microscopy and
Microanalysis at the University of Queensland. Bacterial strains were cultured in THY medium to mid-
exponential phase and treated with PBT2 (6M) and ZnSO4 (500M) for up to 24 h at 37°C. Bacteria were
washed twice preceding glutaraldehyde ﬁxation followed by secondary ﬁxation in 1% osmium tetroxide.
Samples were then dehydrated via a series of ethanol treatments and were applied to coverslips coated with
poly-L-lysine (1mg/ml) before being dried in a critical point dryer (Tousimis) according to the manufacturer’s
instructions. Coverslips were attached to stubs with double-sided carbon tabs and coated with gold using a
sputter coater (SPI) following manufacturer’s instructions. Samples were imaged in a JEOl JSM 7001F or JEOl
JSM 7100F ﬁeld emission SEM at an accelerating voltage of 1 kV.
Accession number(s). The genome of RBWH1 is publicly available under the BioProject identiﬁer
PRJNA497960 (accession numbers CP033206 to CP033212). RNASeq data are available at the GEO
repository (GSE121555).
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